Dyne Therapeutics 为股票发行定价以筹集 $200M，旨在为肌肉疾病治疗提供资金。 Dyne Therapeutics prices stock offering to raise $200M, aiming to fund muscle disease treatments.

专注于治疗遗传驱动肌肉疾病的生物技术公司Dyne Therapeutics已以每股8.25美元的价格公开发行约2424万股股票, 旨在筹集约2亿美元. Dyne Therapeutics, a biotech company focused on treating genetically driven muscle diseases, has priced a public stock offering of about 24.24 million shares at $8.25 each, aiming to raise approximately $200 million. 该公司的股票在前一天以9.52美元关闭后于星期二开放。 The company's stock opened down on Tuesday after closing at $9.52 the previous day. Dyne正在研制治疗方法,治疗诸如心电图萎缩症和Duchenne肌肉萎缩症等疾病。 Dyne is developing treatments for conditions like myotonic dystrophy and Duchenne muscular dystrophy.